BioNTech SE (BSP:B1NT34) Accounts Payable : R$1,892 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is BioNTech SE Accounts Payable?

BioNTech SE's Accounts Payable for the quarter that ended in Dec. 2023 was R$1,892 Mil.

BioNTech SE's quarterly Accounts Payable declined from Jun. 2023 (R$1,202 Mil) to Sep. 2023 (R$1,174 Mil) but then increased from Sep. 2023 (R$1,174 Mil) to Dec. 2023 (R$1,892 Mil).

BioNTech SE's annual Accounts Payable increased from Dec. 2021 (R$1,022 Mil) to Dec. 2022 (R$1,134 Mil) and increased from Dec. 2022 (R$1,134 Mil) to Dec. 2023 (R$1,892 Mil).

BioNTech SE Accounts Payable Historical Data

The historical data trend for BioNTech SE's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Accounts Payable Chart

BioNTech SE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable

Get a 7-Day Free Trial

93.48

640.27

1,022.36

1,134.10

1,891.53

BioNTech SE Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Payable	Get a 7-Day Free Trial															1,134.10	166.74	1,202.12	1,173.80	1,891.53

BioNTech SE Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

BioNTech SE Accounts Payable Related Terms

Thank you for viewing the detailed overview of BioNTech SE's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNTech SE (BSP:B1NT34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (BSP:B1NT34) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

BNTX:USA BNTX:Mexico 0A3M:UK 22UA:Germany BNTX:Austria

Address

An der Goldgrube 12, Mainz, RP, DEU, D-55131

Website

https://www.biontech.de

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.

BioNTech SE (BSP:B1NT34) Headlines

No Headlines